MedTrace Logo

Early Progesterone Cessation After in Vitro Fertilization

NCT01177904 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-04-08

Study results available
· View outcomes & findings →

Summary

There seems to be a general consensus on the supplementation of progesterone (P4) for luteal phase support (LPS) to all women after in vitro fertilization (IVF) treatment. However, there is no agreement about the precise duration of LPS.

Conditions

  • Pregnant Women

Interventions

OTHER

Cease progsterone at 5

Cease administration of progsterone at first US at 5 weeks

OTHER

control group: progesterone 8

Control group: progesterone until 8 weeks of pregnancy

Sponsors & Collaborators

  • IVI Madrid

    lead OTHER

Principal Investigators

  • Juan A Garcia-Velasco, MD, PhD · IVI Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01177904 on ClinicalTrials.gov